List of Prezista drug patents

Prezista is owned by Janssen Prods.

Prezista contains Darunavir.

Prezista has a total of 4 drug patents out of which 0 drug patents have expired.

Prezista was authorised for market use on 23 June, 2006.

Prezista is available in tablet;oral dosage forms.

The generics of Prezista are possible to be released after 26 June, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8518987 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Feb, 2024

(1 year, 18 days from now)

US7700645 JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518987

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Aug, 2024

(1 year, 6 months from now)

US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor
Jun, 2027

(4 years from now)

Drugs and Companies using DARUNAVIR ingredient

Market Authorisation Date: 23 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZISTA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic